Cinvanti is a drug owned by Heron Therapeutics Inc. It is protected by 13 US drug patents filed from 2018 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 18, 2035. Details of Cinvanti's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9808465 | Emulsion formulations of aprepitant |
Sep, 2035
(8 years from now) | Active |
| US9561229 | Emulsion formulations of aprepitant |
Sep, 2035
(8 years from now) | Active |
| US9974794 | Emulsion formulations of aprepitant |
Sep, 2035
(8 years from now) | Active |
| US10953018 | Emulsion formulations of aprepitant |
Sep, 2035
(8 years from now) | Active |
| US12115254 | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
Sep, 2035
(8 years from now) | Active |
| US10624850 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(8 years from now) | Active |
| US9974793 | Emulsion formulations of aprepitant |
Sep, 2035
(8 years from now) | Active |
| US9974742 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(8 years from now) | Active |
| US12115255 | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
Sep, 2035
(8 years from now) | Active |
| US11173118 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(8 years from now) | Active |
| US12290520 | Methods of use of emulsion formulations of aprepitant |
Sep, 2035
(8 years from now) | Active |
| US10500208 | Emulsion formulations of aprepitant |
Sep, 2035
(8 years from now) | Active |
| US11744800 | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
Sep, 2035
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Cinvanti's patents.
Latest Legal Activities on Cinvanti's Patents
Given below is the list of recent legal activities going on the following patents of Cinvanti.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 24 Nov, 2025 | US9974794 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 24 Nov, 2025 | US9974793 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 24 Nov, 2025 | US9974742 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 16 May, 2025 | US11173118 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 07 May, 2025 | US9808465 |
| Recordation of Patent eGrant | 06 May, 2025 | US12290520 |
| Patent Issue Date Used in PTA Calculation | 06 May, 2025 | US12290520 |
| Recordation of Patent Grant Mailed | 06 May, 2025 | US12290520 |
| Email Notification | 06 May, 2025 | US12290520 |
| Patent eGrant Notification | 06 May, 2025 | US12290520 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets
invalidated somehow, the
generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal
pitfalls. Given
below are details of the litigation history of Cinvanti and ongoing
litigations to
help you estimate the early arrival of Cinvanti generic.
Cinvanti's Litigations
Cinvanti been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 28, 2025, against patent number US12115255. The petitioner Azurity Pharmaceuticals, Inc. et al., challenged the validity of this patent, with Heron Therapeutics, Inc. as the respondent. Click below to track the latest information on how companies are challenging Cinvanti's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US12115254 | February, 2025 |
Discretionary Denial
(14 Aug, 2025) | Heron Therapeutics, Inc. | Azurity Pharmaceuticals, Inc. et al. |
| US12115255 | February, 2025 |
Discretionary Denial
(14 Aug, 2025) | Heron Therapeutics, Inc. | Azurity Pharmaceuticals, Inc. et al. |
US patents provide insights into the exclusivity only within the United States, but
Cinvanti is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Cinvanti's family patents as well as insights into
ongoing legal events
on those patents.
Cinvanti's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Cinvanti:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Cinvanti's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 18, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cinvanti Generic API suppliers:
Aprepitant is the generic name for the brand Cinvanti. 4 different companies have already filed for the generic of Cinvanti, with Glenmark Speclt having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cinvanti's generic
How can I launch a generic of Cinvanti before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Cinvanti's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Cinvanti's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Cinvanti -
| Strength | Submission Date | Expiration Date of Last Qualifying Patent | 180-Day Status | First Applicant Approval | Generic Competition Status |
|---|---|---|---|---|---|
| 29 Apr, 2022 | 18 Sep, 2035 | Non-Forfeiture | Less |
Alternative Brands for Cinvanti
Cinvanti which is used for managing nausea and vomiting in cancer patients undergoing chemotherapy., has several other brand drugs using the same active ingredient (Aprepitant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Heron Theraps Inc |
| |
| Merck And Co Inc |
| |
| Msd |
| |
| Msd Merck Co |
| |
| Steriscience |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Aprepitant, Cinvanti's active ingredient. Check the complete list of approved generic manufacturers for Cinvanti
About Cinvanti
Cinvanti is a drug owned by Heron Therapeutics Inc. It is used for managing nausea and vomiting in cancer patients undergoing chemotherapy. Cinvanti uses Aprepitant as an active ingredient. Cinvanti was launched by Heron in 2017.
Approval Date:
Cinvanti was approved by FDA for market use on 09 November, 2017.
Active Ingredient:
Cinvanti uses Aprepitant as the active ingredient. Check out other Drugs and Companies using Aprepitant ingredient
Treatment:
Cinvanti is used for managing nausea and vomiting in cancer patients undergoing chemotherapy.
Dosage:
Cinvanti is available in emulsion form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 130MG/18ML (7.2MG/ML) | EMULSION | Prescription | INTRAVENOUS |